{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:45:17Z","timestamp":1701960317629},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T00:00:00Z","timestamp":1495238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The present phase 3, randomized, open\u2010label study compared the efficacy and safety of basal insulin peglispro with insulin glargine after 26\u00a0weeks of treatment when added to oral antihyperglycemic medications in insulin\u2010na\u00efve Asian patients with type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The primary objective was to show non\u2010inferiority of the change in glycated hemoglobin from baseline to 26\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 26\u00a0weeks, insulin peglispro was non\u2010inferior to glargine, meeting the primary objective. Patients receiving insulin peglispro (<jats:italic>n<\/jats:italic>\u00a0=\u00a0192) showed a greater reduction in glycated hemoglobin from baseline compared with glargine (<jats:italic>n<\/jats:italic>\u00a0=\u00a0196); \u22121.6 vs \u22121.4%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.005) and in fasting serum glucose (\u221261.2 vs \u221254.8\u00a0mg\/<jats:styled-content style=\"fixed-case\">dL<\/jats:styled-content>,<jats:italic> P<\/jats:italic>\u00a0=\u00a00.02). A significantly higher proportion of patients receiving insulin peglispro achieved glycated hemoglobin &lt;7% (57 vs 44%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.012). Insulin peglispro patients showed significantly less weight gain from baseline (1.1 vs 1.6\u00a0kg, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.03). Relative rates (insulin peglispro\/glargine) of total and nocturnal hypoglycemia through 26\u00a0weeks were 1.06 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.67) and 0.7 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.10), respectively. Significantly more insulin peglispro\u2010treated patients experienced adverse events compared with glargine\u2010treated patients (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.042). Alanine aminotransferase and aspartate aminotransferase were significantly increased from baseline with insulin peglispro compared with glargine at week 26 (3.5 vs \u22124.6\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/L and 2.8 vs \u22121.5\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/L, respectively; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). The incidence of injection site reactions was low and did not differ between the treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Insulin peglispro provided better glycemic control vs glargine with no differences in hypoglycemia and increased aminotransferases in insulin\u2010na\u00efve Asian patients with type 2 diabetes.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.12667","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T20:28:11Z","timestamp":1491251291000},"page":"100-107","source":"Crossref","is-referenced-by-count":2,"title":["Open\u2010label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin\u2010na\u00efve Asian patients with type 2 diabetes"],"prefix":"10.1111","volume":"9","author":[{"given":"Takahisa","family":"Hirose","sequence":"first","affiliation":[{"name":"Toho University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Cai","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwee Poo","family":"Yeo","sequence":"additional","affiliation":[{"name":"Lilly\u2010NUS Singapore, Medical Drive Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Imori","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ohwaki","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Imaoka","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2015.30.3.263"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12098"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2004.02.012"},{"issue":"1","key":"e_1_2_7_5_1","first-page":"S1","article-title":"Standards of medical care in diabetes","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_7_6_1","unstructured":"The Japan Diabetes Society.Evidence\u2010Based Practice Guideline for the Treatment of Diabetes in Japan 2013.Nankodo Co . Ltd Bunkyo\u2010ku Tokyo Japan 2013. Available from:http:\/\/www.jds.or.jp\/modules\/en\/index.php?content_id=44Accessed January 20 2017 (in Japanese)"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0220"},{"key":"e_1_2_7_8_1","first-page":"41","article-title":"Effectiveness of basal\u2010supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes","volume":"37","author":"Suzuki D","year":"2012","journal-title":"Tokai J Exp Clin Med"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2011.00137.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"issue":"1","key":"e_1_2_7_11_1","first-page":"S23","article-title":"LY2605541: leveraging hydrodynamic size to develop a novel basal insulin","volume":"55","author":"Beals JM","year":"2012","journal-title":"Diabetologia"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12744"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12712"},{"key":"e_1_2_7_14_1","unstructured":"World Health Organization.Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. 14 January2006. Available from:http:\/\/www.who.int\/diabetes\/publications\/Definition%20and%20diagnosis%20of%20diabetes_new.pdfAccessed January 20 2017."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2006.08.012"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2007.08.007"},{"key":"e_1_2_7_17_1","unstructured":"Center for Drug Evaluation and Research Food and Drug Administration.Guidance for industry: Drug\u2010induced liver injury: Premarketing clinical evaluation.2009. Available from:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdfAccessed January 20 2017."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12757"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.621416"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12743"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12102"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1205"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12618"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"issue":"1","key":"e_1_2_7_25_1","first-page":"A251","article-title":"Lipid changes during 26\u2010wk treatment with the novel basal insulin peglispro (BIL) vs. insulin glargine (GL) or insulin NPH in 6 IMAGINE trials","volume":"64","author":"Ginsberg H","year":"2015","journal-title":"Diabetes"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1531"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(90)90020-J"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-62-3-605"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12751"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.12667","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:36:33Z","timestamp":1695537393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.12667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/jdi.12667"],"URL":"https:\/\/doi.org\/10.1111\/jdi.12667","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,20]]}}}